GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transition Therapeutics Inc (NAS:TTHI) » Definitions » Short Percentage of Float

Transition Therapeutics (Transition Therapeutics) Short Percentage of Float


View and export this data going back to 2007. Start your Free Trial

What is Transition Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Transition Therapeutics's Short Percentage of Float

For the Biotechnology subindustry, Transition Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Transition Therapeutics's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transition Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Transition Therapeutics's Short Percentage of Float falls into.


Transition Therapeutics (Transition Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transition Therapeutics Inc (NAS:TTHI) » Definitions » Short Percentage of Float
Comparable Companies
AGE ASX:MDC TSX:BU BKK:IP OPNT OHEL:HRTIS XPAR:GNRO NLNK MRNS GNCA XKRX:038070 ROCO:6696 TSXV:MPH OSTO:DMYD B CYCN XTER:CNWK TSE:4570 KZR BVXV XMAD:BIO
Traded in Other Exchanges
N/A
Address
Website
http://www.transitiontherapeutics.com
Transition Therapeutics Inc was incorporated on July 6, 1998 as 'Transition Therapeutics and Diagnostics Inc.' The Corporation filed articles of amendment on October 12, 2000 and on October 19, 2000 to create a class of non-voting shares (the 'Class B Shares') and to amend certain attributes of its Common Shares. On November 2, 2000, the Corporation filed articles of amendment to delete its private company restrictions. On December 14, 2000, the Corporation filed articles of amendment to change its name to 'Transition Therapeutics Inc.' The Company's technologies are focused on the treatment of Alzheimer's disease and diabetes. The Corporation operates in one business segment; that is the research and development of therapeutic agents. Its technologies in development include ELND005 (AZD-103) for the treatment of Alzheimer's disease. On April 30, 2013, the Company announced the results of a five-week proof of concept clinical study of TT401 in type 2 diabetic and obese non-diabetic subjects. In the study, TT401, a once weekly administered peptide, demonstrated improvements in glycemic control and reductions in body weight.
Executives
Jack W Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Family Foundation Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045